CRS-207 for Cancer of Pancreas

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Cancer of Pancreas+1 More
CRS-207 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a new drug combination can improve survival in people with pancreatic cancer.

See full description

Eligible Conditions

  • Cancer of Pancreas
  • Malignant Neoplasm of Pancreas

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether CRS-207 will improve 1 primary outcome and 1 secondary outcome in patients with Cancer of Pancreas. Measurement will happen over the course of 4 years.

4 years
Number of participants experiencing grade 3 or above drug-related toxicities
Objective response rate (irORR) using immune Response Evaluation Criteria for Solid Tumors (iRECIST)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Arm A - Tadalafil, Pembrolizumab, Ipilimumab, CRS-207
1 of 1
Experimental Treatment

This trial requires 20 total participants across 1 different treatment group

This trial involves a single treatment. CRS-207 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Arm A - Tadalafil, Pembrolizumab, Ipilimumab, CRS-207
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CRS-207
2015
Completed Phase 2
~490
Ipilimumab
FDA approved
Tadalafil
FDA approved
Pembrolizumab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 4 years for reporting.

Closest Location

Sidney Kimmel Comprehensive Cancer Center - Baltimore, MD

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
The Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 means that a person is fully able to carry out all normal activities and has no problems with activities of daily living. show original
Patients who have at least one tumor that can be measured. show original
study The patient was willing to have a tumor biopsy at the beginning of the study and throughout the study. show original
The patients in the study must have organ and marrow function that is adequately defined by the laboratory tests specified in the study. show original
For both Women and Men, it is required to use an acceptable form of birth control while on the study. show original
The ability to understand and willingness to sign a written informed consent document are important factors when considering whether to participate in a clinical trial. show original
18 years or older. show original
Have a confirmed diagnosis of pancreatic adenocarcinoma. show original
Have previously treated metastatic cancer. show original
Pathologic stage pt2n2m0 The patient has radiographic evidence of disease progression and is at pathologic stage pt2n2m0. show original

Patient Q&A Section

Is crs-207 typically used in combination with any other treatments?

"We recommend CrS 207 as a first line therapy in patients with metastatic pancreatic cancer. A phase II trial (CRISP 2) comparing this agent with gemcitabine alone failed to demonstrate a difference in OS or PFS. However, significant toxicity was seen with CrS 207 (relative to gemcitabine alone), including grade 3/4 rash and diarrhoea." - Anonymous Online Contributor

Unverified Answer

What is crs-207?

"CRS-207 is an experimental immunogen developed as a novel therapeutic strategy against solid tumors. CRS-207 is a synthetic lipopeptide (a short peptide chain linked to a lipid molecule) designed to elicit a specific immune response against solid tumors. CRS-207 is intended to activate dendritic cells (DCs) to stimulate CD8+ T cells specifically against tumors. Dendritic cells drive the immune response by presenting tumor antigens on their cell membranes to T-cells, thus stimulating an antitumor immune response. By triggering this immune response against tumors, CRS-207 represents a promising approach for eliciting an effective anti-tumor immune response." - Anonymous Online Contributor

Unverified Answer

What causes cancer of pancreas?

"Causes of [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) include hereditary pancreatobiliary cancers, chronic pancreatitis, cholelithiasis, and pancreatic adenocarcinoma. Genetic predisposition is important factor in developing pancreatic cancer, but many other factors also play role.\n\nNormally, the pancreas is protected from infection by lymphocytes (white blood cells), macrophages, and an array of chemical toxins produced by the pancreas. Thus, most infections do not affect the pancreas. However, if the pancreatic duct becomes inflamed, obstruction of drainage of the pancreas can occur. Pancreatic fluid stays stagnant, leading to bacterial colonization, inflammation, and cell death." - Anonymous Online Contributor

Unverified Answer

What are common treatments for cancer of pancreas?

"The most common first line treatment for pancreatic cancer is surgery. However, chemotherapy is widely used as an adjuvant therapy. Chemotherapy, radiotherapy, and targeted therapy are also used to treat some kinds of pancreatic cancers." - Anonymous Online Contributor

Unverified Answer

How quickly does cancer of pancreas spread?

"We can conclude that cancer of pancreas spreads rapidly but stays localized in body. The immediate response to curative treatment is quick, and overall survival is good." - Anonymous Online Contributor

Unverified Answer

What is the latest research for cancer of pancreas?

"The current research is focused on several fields including pancreatic cancer, distant metastases, peritoneal carcinomatosis in resected pancreatic adenocarcinoma, and multimodality therapy for unresectable pancreatic cancer. However, there is no published meta-analysis or systematic review about the exact prognostic value of the different tumor markers in pancreatic cancer. Further prospective studies are necessary to understand the real role of each marker in predicting survival and recurrence." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for cancer of pancreas?

"Cancer patients who need new therapies or have not received satisfactory treatment should be considered candidates for clinical trials. However, a number of characteristics may be helpful in selecting the best patient candidate. These include age, sex, performance status, comorbidities, tumor burden, and surgical resection. In addition, clinicians should consider the appropriateness of the intervention being investigated in the trial and the likelihood that it will yield meaningful results." - Anonymous Online Contributor

Unverified Answer

What is cancer of pancreas?

"Pancreatic cancer is the third leading cause of cancer death in the United States and affects about 35,000 people each year. In this article, we discuss the signs and symptoms of pancreatic cancer and how to detect it; describe what's happening at the cellular level as pancreatic cancer develops; and explain why some pancreatic cancers respond to chemotherapy while others do not. We also look at the different types of pancreatic cancers and how they can be diagnosed and treated." - Anonymous Online Contributor

Unverified Answer

Does crs-207 improve quality of life for those with cancer of pancreas?

"Findings from a recent study of our study suggest that crs-207 may have utility as a topical, noninvasive, and inexpensive means of improving quality of life for patients with unresectable pancreatic cancer." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets cancer of pancreas?

"Cancer of pancreas occurs at any age; however, it is more common among people who were younger than 45 years old and older than 65. About half of all cases occur in women and about one third in men." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating cancer of pancreas?

"There have been no new discoveries in the development of medicines for the treatment of pancreatic cancer. The only treatments currently available include surgery, radiotherapy, chemotherapy, biologic therapy, and targeted therapy.\n" - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Cancer of Pancreas by sharing your contact details with the study coordinator.